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Context: GDF15 is a stress-induced hormone acting in the hindbrain that activates neural circuitry 
involved in establishing aversive responses and reducing food intake and body weight in animal models. 
Anorexia, weight loss, nausea and vomiting are common manifestations of glucocorticoid deficiency, 
and we hypothesized that glucocorticoid deficiency may be associated with elevated levels of GDF15.
Objective: To determine the impact of primary adrenal insufficiency (PAI) and glucocorticoid 
replacement on circulating GDF15 levels.
Methods and Results: We measured circulating concentrations of GDF15 in a cohort of healthy 
volunteers and Addison’s disease patients following steroid withdrawal. Significantly higher GDF15 
(mean ± standard deviation [SD]) was observed in the Addison’s cohort, 739.1 ± 225.8 pg/mL compared 
to healthy controls, 497.9 ± 167.7 pg/mL (P = 0.01). The effect of hydrocortisone replacement on 
GDF15 was assessed in 3 independent PAI cohorts with classical congenital adrenal hyperplasia or 
Addison’s disease; intravenous hydrocortisone replacement reduced GDF15 in all groups. We examined 
the response of GDF15 to increasing doses of glucocorticoid replacement in healthy volunteers with 
pharmacologically mediated cortisol deficiency. A dose-dependent difference in GDF15 (mean ± SD) was 
observed between the groups with values of 491.0 ± 157.7 pg/mL, 427.0 ± 152.1 pg/mL and 360 ± 143.1 
pg/mL, in the low, medium and high glucocorticoid replacement groups, respectively, P < .0001.
Conclusions: GDF15 is increased in states of glucocorticoid deficiency and restored by glucocorticoid 
replacement. Given the site of action of GDF15 in the hindbrain and its effects on appetite, further 
study is required to determine the effect of GDF15 in mediating the anorexia and nausea that is a 
common feature of glucocorticoid deficiency. (J Clin Endocrinol Metab 105: 1–8, 2020)
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GDF15 (then called MIC-1) was first identified in 1997 as a novel transcript from a macrophage 
cell line and classified as a member of the transforming 
growth factor beta (TGF-β) superfamily (1). However, 
in humans, GDF15 is widely expressed with highest 
levels seen in placental trophoblasts followed by kidney, 
bladder, prostate, gastrointestinal, pancreatic, lung, liver, 
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and adipose tissue (2). GDF15 has been proposed as a 
marker of cellular stress with elevated circulating levels 
observed in a number of physiological and pathological 
states (3). Conditions where increased circulating GDF15 
have been reported include but are not limited to preg-
nancy, exercise, aging, renal failure, cardiac failure, 
chronic inflammatory disease, neoplasia, and mitochon-
drial diseases as well as cytotoxic chemotherapy and ion-
izing radiation (3). Aligned with the view that GDF15 
represents a marker of cellular stress, increased expression 
and secretion of GDF15 has been demonstrated when 
the cellular integrated stress response  (ISR) pathway 
is activated (4, 5, 6) suggesting that GDF15 represents 
an endocrine arm of the cellular ISR. Key advances in 
our understanding of the functional biology of GDF15 
have come from the observations that (i) overexpression 
of GDF15 in mice resulted in weight loss and reduced en-
ergy intake (7); (ii) GDF15 knockout mice have increased 
body mass and energy intake compared to wild-type 
counterparts (8); and (iii) GDF15 seemingly mediates 
these effects on energy intake and body mass through the 
hind brain (9). Subsequently, glial-derived neurotrophic 
factor receptor alpha-like (GFRAL) was identified as the 
ligand binding component of the heterodimeric receptor 
for GDF15 (10–13). GFRAL expression is highly specific 
to the area postrema and nucleus tractus solitarius of 
the hindbrain where it is required to mediate the weight 
lowering effects of GDF15. There is compelling evidence 
in rodents and non-human primates that manipulation 
of the GDF15-GFRAL pathway induces an anorectic 
effect (10–13). At present, evidence supporting the an-
orectic potential of GDF15 in humans is largely limited 
to observational studies. Increased GDF15 in a range of 
cancer types has been reported to associate with weight 
loss and is implicated in the pathogenesis of cancer cach-
exia (7, 14–16). Similar associations have been observed 
in cardiac failure where higher GDF15 serves not only 
as a biomarker for mortality risk but there is an inverse 
relationship seen between GDF15 and body mass index 
(BMI) (17). In chronic kidney disease (CKD), GDF15 is 
also predictive of mortality. Higher levels of GDF15 have 
been reported in dialysis patients who had protein energy 
wasting, while among CKD patients increasing tertiles 
of GDF15 are associated with decreasing BMI (18, 19). 
Therapeutically targeting the GDF15–GFRAL axis has 
gained considerable attention in the management of an-
orexia and cachexia associated with cancer and other 
chronic diseases (20).
However, it is not clear why a stress induced hormone 
such as GDF15 should primarily reduce energy intake. 
It has been proposed that GDF15 may have evolved ori-
ginally to provide a signal to the organism that a harmful 
toxin has been ingested, with the brainstem-derived 
signal serving in the acute setting to reduce continued 
ingestion and in the longer term to avoidance upon fu-
ture encounters (21). In support of this hypothesis is 
genetic (22) and biochemical (23) evidence in humans 
implicating GDF15 in the pathogenesis of the nausea 
and vomiting of pregnancy, including hyperemesis 
gravidarum. Further, at least at pharmacological doses, 
recombinant GDF15 induces a conditioned taste aver-
sion in rodents (4). Moreover, the emetic potential of 
GDF15 was recently illustrated in response to adminis-
tration of the peptide to musk shrews (24). Collectively, 
these observations suggest that GDF15 has aversive 
properties and this may underpin its effect on energy 
intake.
Primary adrenal insufficiency (PAI) is a rare condition 
with a reported prevalence of between 100 to 140 cases 
per million and represents a potentially life-threatening 
illness that is characterized by the impaired ability of the 
adrenal cortex to produce sufficient amounts of gluco-
corticoid and/or mineralocorticoid (25). Glucocorticoids 
are produced and secreted under the control of adreno-
corticotropin and regulate a number of basal and 
stress-mediated physiological responses that include in-
flammatory, metabolic, and hemodynamic processes (26, 
27) while mineralocorticoids are under the regulation of 
the renin–angiotensin system and play a key role in fluid 
and electrolyte balance (28). Although a number of dif-
ferent etiologies are responsible, patients with PAI share 
common clinical features attributable to deficiency of the 
respective steroid hormones (25, 29). To date, there are 
no reports on the effect of glucocorticoid deficiency on 
circulating GDF15. Among individuals diagnosed with 
PAI symptoms of nausea, vomiting, and anorexia are re-
ported in greater than two-thirds of those affected and 
responsive to hormone replacement (29). In some in-
stances, the severity of such symptoms has led to the mis-
diagnosis of PAI as anorexia nervosa (30) or presented as 
intractable vomiting (31). We hypothesized that GDF15 
would be increased in the setting of glucocorticoid de-
ficiency and may contribute to the nausea/vomiting/
anorexia phenotype frequently observed in adrenal in-
sufficiency. To explore this, we measured circulating 
GDF15 in volunteers with PAI and pharmacologically 
induced glucocorticoid deficiency and determined its re-
sponse to glucocorticoid replacement.
Methodology
Cohort 1: Addison’s disease
The study was approved by the Ethics Review Board 
of the University of Gothenburg, Sweden (permit 
no. 374-13, August 8, 2013) and written informed con-
sent was obtained from all patients before participation. 
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This was a randomized cross-over, single-blinded trial 
including subjects with Addison’s disease who received 
in random order intravenous hydrocortisone infusion in 
isotonic saline in a circadian pattern or the same volume 
of isotonic saline for 22 hours, at least 2 weeks apart. 
Dosing of the hydrocortisone infusion was adapted 
from Kerrigan et  al (32). The intravenous hydrocorti-
sone (Solu-Cortef) infusion was initiated from 0900h 
at starting at a dose of 0.024 mg/kg/h before being de-
creased gradually to achieve a dose of 0.008 mg/kg/h by 
0000h, at which point the dose was increased to 0.03mg/
kg/h and maintained until blood sampling at 0700h. 
Daily replacement doses of hydrocortisone were with-
drawn for 17 hours prior to initiation of the infusion. 
Subjects omitted their usual fludrocortisone dose (when 
prescribed) the day before and during each interven-
tion. Ten subjects (4 women and 6 men) with Addison’s 
disease with a mean ± SD age of 46.6 ± 9.4 years, BMI 
of 25.6 ± 2.5 kg/m2 and a median disease duration of 
23.5 years (min–max, 1–33) were included in the study. 
The median daily replacement dose of hydrocortisone 
prior to the study was 30 mg (min–max, 20–30).
Cohort 2: Addison’s disease
Full details of this protocol have been published 
previously (33). Ethical approval from the South East 
Scotland Research Ethics committee and informed 
consent were obtained from all participants. In brief, 
subjects with Addison’s disease attended the Edinburgh 
Clinical Research Facility after an  overnight fast and 
having omitted their usual glucocorticoid morning dose. 
Subjects omitted their usual fludrocortisone dose (when 
prescribed) the day before and on the morning of their 
visits. Serum samples obtained from eight subjects (6 
female, 2 male, mean ± SD age 51.6 ± 14.8 years  and 
BMI 25.1  ±  3.6  kg/m2) at baseline t  =  0  min and fol-
lowing 320  min of a 3-step intravenous infusion of 
9,11,12,12-[2H]4-hydrocortisone were analyzed for 
GDF15. Mean ± SD cortisol concentrations at baseline 
were 28.2 ± 41.0 nmol/L and by t + 320 min deuterated 
cortisol concentrations were 410.9 ± 255.7 nmol/L.
Cohort 3: Congenital adrenal hyperplasia
Nine subjects (7 female, 2 male, mean ± SD 
age 38.7 ± 12.2 years and BMI 32.1 ± 12.3 kg/m2) with 
classic congenital adrenal hyperplasia (CAH) secondary 
to 21-hydroxylase deficiency were recruited to a random-
ized double-blind crossover study comparing placebo 
and hydrocortisone infusion as part of a separate study 
protocol. Ethical approval from the South East Scotland 
Research Ethics committee and informed consent were 
obtained from all participants. Subjects attended the 
Edinburgh Clinical Research Facility after overnight fast 
and omitting their usual glucocorticoid treatment from 
1800h onwards the previous day, although subjects still 
took their usual fludrocortisone dose that morning if pre-
scribed. Subjects received either an intravenous infusion 
of hydrocortisone for 300  min (following a 2.6  μmol 
bolus hydrocortisone was infused at 51.5  nmol/min 
from t = 0 min until t + 150 min, then following a fur-
ther 2.6 μmol intravenous bolus the hydrocortisone was 
infused at 103 nmol/min until the end of the protocol) or 
placebo (0.9% sodium chloride). Plasma samples obtained 
at baseline and at the end of the infusion during both visits 
were analyzed for GDF15 concentrations. Mean ± SD cir-
culating cortisol concentrations were 32.5 ± 30.4 nmol/L 
at baseline and rose to 493.9 ± 79.8 nmol/L at t + 300 min 
of the hydrocortisone infusion, while cortisol levels were 
26.8 ± 23.4 nmol/L at baseline and 20.4 ± 18.1 nmol/L at 
t + 300 min of the placebo infusion.
Cohort 4: Pharmacological cortisol deficiency
Full details of this protocol have been published previ-
ously (34). Ethical approval from the South East Scotland 
Research Ethics committee and informed consent was 
obtained from all participants. In brief, 20 male subjects 
(Mean ± SD age 33.4 ± 15.6 years and BMI 23.8 ± 1.6 kg/
m2) were recruited to a randomized double-blind cross-
over study comparing the effects of low, medium, and high 
cortisol concentrations. Subjects attended the Edinburgh 
Clinical Research Facility on 3 separate occasions 
after overnight fast. Subjects all received the 11-beta-
hydroxylase inhibitor metyrapone, 1 g orally at 2200h the 
night before and at 0700h and 1100h on the morning of 
each assessment to inhibit endogenous cortisol synthesis. 
Subjects received either placebo (low cortisol phase) or 
hydrocortisone tablets (10 mg at 2200h the night before 
and 5 mg at 0700h on medium cortisol phase, 20 mg at 
2200h the night before and 10 mg at 0700h on high cor-
tisol phase) in random order. Upon arrival at the research 
facility, subjects received an intravenous infusion of either 
0.9% sodium chloride (placebo phase) or hydrocortisone 
(at 0.025 mg/kg/h following a 0.04 mg/kg bolus [medium 
cortisol phase] or at 0.12 mg/kg/h following a 0.18 mg/kg 
bolus [high cortisol phase]) for 345 min. Plasma samples 
obtained at 285 min of the infusion were analyzed for 
GDF15. Mean ± SD cortisol concentrations at 285 min 
of the infusion were 170.2 ± 54.0 (low), 464.9 ± 90.2 
(medium), and 1479.4 ± 246.6 (high) nmol/L for the re-
spective phases.
Healthy volunteer study
The study was approved by the Cambridge central 
research ethics committee (REC 06/Q0108/84) and 
written informed consent were obtained from all partici-
pants prior to participation in the study. Ten participants 
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from the healthy volunteer study were selected as an age, 
sex, and BMI matched control group for participants 
from cohort 1 with Addison’s disease. Exclusion criteria 
were (i) age <17 or >65 years; (ii) pregnancy or breast 
feeding; (iii) any current or past medical disorder that 
could affect the reference measurements; (iv) any cur-
rent or previous medical disorder that could influence a 
participant’s ability to follow the study protocols safely 
and effectively; (v) any current or previous medication 
that affect the reference measurements; (vi) current or 
previous drug or alcohol abuse; (vii) current smoking 
habit; and (viii) any concern that a participant may not 
understand study protocols sufficiently to give informed 
consent. Volunteers attended the National Institute for 
Health Research (NIHR) Cambridge Clinical Research 
Facility for assessment where study bloods were taken 
from the participants at 0800h following an overnight 
fast. GDF15 and cortisol were measured on serum col-
lected from the 10 participants.
Biochemical assays
Cortisol. Cohort 1, 2, 3: Endogenous and deuter-
ated cortisol concentrations were analyzed by liquid-
chromatography tandem mass spectrometry (ABSciex 
Qtrap 5500 with Waters Acquity UPLC; Column: ACE 
Excel C18-AR 2.1×150mm) as previously described 
(33) at the Mass Spectrometry Core Laboratory, Centre 
for Cardiovascular Science, Queen’s Medical Research 
Institute in Edinburgh, UK. Cohort 4: Cortisol was meas-
ured by radioimmunoassay as previously described (34). 
Healthy volunteer study. Serum cortisol was measured 
using LC-MS/MS at Cambridge university hospital NHS 
foundation trust. Serum proteins were precipitated and 
cortisol released from its binding proteins using ZnSO4 
precipitation. The sample was processed using online 
solid phase extraction then HPLC separation using a 
pheny-hexyl column. Deuterated cortisol was used as an 
internal standard. Mass transitions used are 363.3/121.2 
(quantifier) 363.3/327.3 (qualifier) and 367.3 /121.1 (in-
ternal standard). An APISciex 550 mass spectrometer 
was used with APCI ionization in positive ion mode.
GDF15. GDF15 measurements on all participants’ 
serum or plasma was undertaken at the Cambridge 
Biochemical Assay Laboratory, University of 
Cambridge, using antibodies and standards from 
R&D Systems (R&D Systems Europe, Abingdon UK). 
GDF15 was measured using a microtiter plate-based 
2-site electrochemiluminescence immunoassay with the 
MesoScale Discovery assay platform (MSD, Rockville, 
Maryland, US).
Statistical analysis
Data are presented as mean  ±  SD unless otherwise 
stated. Data were analyzed using Graphpad Prism® 
Version 6.  Differences between the means were com-
pared using paired and unpaired 2 sample student 
t-tests as indicated. A one-way analysis of variance and 
post-hoc Tukey test was used to test differences between 
means where >2 groups were present. The null hypoth-
esis was rejected at P < .05.
Results
Primary adrenal insufficiency is associated with 
increased GDF15 levels
To determine whether circulating levels of GDF15 
among patients with PAI differed significantly from 
those of healthy volunteers, we compared GDF15 and 
cortisol measurements from patients with PAI due 
to Addison’s disease in  cohort 1 (male n  =  6, female 
n = 4, age 46.4 ± 9.4 years, BMI 25.6 ± 2.5 kg/m2) to 
a matched control group from the healthy volunteer 
study (male n = 6, female n = 4, age 43.6 ± 11.7 years, 
BMI 25.4 ± 3.6 kg/m2). Patients with Addison’s disease 
had their glucocorticoid and mineralocorticoid therapy 
withdrawn for at least 39 hours (see methods—placebo 
group cohort 1) prior to measurement of morning cortisol 
and GDF15. As expected, serum cortisol levels were sig-
nificantly lower among patients with Addison’s disease 
than the matched control group, 46.5  ±  16.9  nmol/L 
versus 370.7 ± 71.55 nmol/L (P <  .0001), respectively 
(Fig.  1A). We observed significantly higher levels of 
GDF15 in the Addison’s disease cohort who were gluco-
corticoid deficient than in the matched healthy volun-
teer cohort 739.1 ± 225.8 pg/mL versus 497.9 ± 167.7 
pg/mL (P = .01), respectively (Fig. 1B).
Glucocorticoid replacement reduces circulating 
GDF15 in primary adrenal insufficiency
To determine the effect of correcting glucocorticoid 
deficiency on GDF15, ten participants (male  =  6, fe-
male  =  4) with Addison’s disease (cohort 1)  were as-
sessed on 2 occasions. Glucocorticoid treatment was 
withdrawn for 17  hours before they were random-
ized to receive a hydrocortisone infusion mimicking 
physiological glucocorticoid action from 0900h to 
0700h or an infusion of normal saline in a crossover 
design. Circulating cortisol levels were significantly 
higher at 0700h following the glucocorticoid inter-
vention compared to placebo 362  ±  292.9  nmol/L 
versus 46.5  ±  16.9  nmol/L (P  =  .006), respectively. 
GDF15 was significantly increased during the placebo 
infusion at 739.1  ±  225.8 pg/mL when compared to 
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the hydrocortisone infusion 558.5  ±  119.9, P  =  .017 
(Fig.  2A). To evaluate the reproducibility of the ob-
servation that glucocorticoid replacement in PAI was 
associated with a reduction in circulating GDF15 we 
assessed 2 independent PAI cohorts comprising of pa-
tients with Addison’s disease (cohort 2)  or classical 
CAH (cohort 3). Maintenance glucocorticoid therapy 
was withdrawn for at least 18 hours in the Addison’s 
cohort, GDF15 was measured at baseline and following 
320 min of hydrocortisone infusion. There was a sig-
nificant reduction in circulating GDF15 following the 
infusion (610.4  ±  153.4 pg/mL) when compared to 
baseline (753.8 ± 226.4 pg/mL, P = .008) (Fig. 2B). The 
CAH cohort was studied on 2 occasions following the 
withdrawal of maintenance glucocorticoid replacement 
therapy (for at least 14 h prior to attendance), each par-
ticipant received an isotonic saline or hydrocortisone 
infusion over 300 min. Baseline GDF15 levels did not 
differ significantly between the placebo (659.1 ± 177.7 
pg/mL) and glucocorticoid (667.0 ± 206.0 pg/mL) study 
visits (P = .760). Circulating GDF15 levels were signifi-
cantly lower when participants (n = 8) received a 300-
min infusion of hydrocortisone (547.0 ± 137.0 pg/mL) 
than the normal saline placebo infusion (606.0 ± 129.8 
pg/mL), P = .014 (Fig. 2C).
Glucocorticoid replacement demonstrates a dose-
dependent relationship with GDF15
We hypothesized that a dose-dependent relationship 
existed between glucocorticoid replacement in PAI and 
GDF15 levels. To explore this, we determined the effect 
of low, medium, or high dose hydrocortisone replace-
ment in 20 healthy male volunteers whose endogenous 
cortisol production had been pharmacologically 
Figure 1. Circulating GDF15 is increased in primary adrenal insufficiency. (A) Early morning serum cortisol levels are significantly lower in 10 
patients with Addison’s disease (AD) following withdrawal of maintenance glucocorticoid therapy when compared to a cohort of healthy matched 
control participants (n = 10). (B) Serum GDF15 measured in parallel with cortisol sampling was significantly higher within the steroid deficient 
Addison’s disease cohort than in the control group. Data presented as mean ± standard deviation and compared using an unpaired t-test. *P < .05 
and ****P < .0001.
Figure 2. Hydrocortisone replacement reduces GDF15 in primary adrenal insufficiency. (A) Ten adult volunteers with Addison’s disease 
who had glucocorticoid therapy withdrawn demonstrated significantly lower GDF15 levels following a 22-h intravenous infusion of hydrocortisone 
(red circles) compared to the equivalent infusion of normal saline (black circles). (B) GDF15 levels reduced significantly from baseline measurements 
following infusion of hydrocortisone in 8 participants with Addison’s disease following withdrawal of glucocorticoid therapy. (C) Among 9 
participants with CAH whose glucocorticoid therapy was withdrawn, baseline GDF15 levels did not differ significantly between placebo (black 
circles) and hydrocortisone (black squares) visits. GDF15 levels were significantly lower in participants (n = 8) who received the hydrocortisone 
infusion (red squares) when compared to those receiving placebo (red circles). Data expressed as mean ± standard deviation and compared using a 
paired t-test, *P < .05 and **P < .01.
doi:10.1210/clinem/dgz277 https://academic.oup.com/jcem  5
Copyedited by: OUP
D
ow
nloaded from
 https://academ
ic.oup.com
/jcem
/article-abstract/105/5/dgz277/5680613 by guest on 02 April 2020
inhibited by metyrapone (cohort 4). We observed a 
significant and progressive reduction in GDF15 in re-
sponse to increasing hydrocortisone doses (low dose 
= 491.1 ± 157.6 pg/mL; medium dose = 427.2 ± 152.2 
pg/mL; high dose = 360.3 ± 143.1 pg/mL; analysis of 
variance P < .0001) (Fig. 3).
Discussion
Our hypothesis that glucocorticoid may modulate 
GDF15 levels was based on two previous lines of evi-
dence. First, glucocorticoids have been reported to 
reduce GDF15 gene expression (35, 36). Second, gluco-
corticoids have well established antiemetic properties, 
which are used clinically, particularly in the context 
of cytotoxic chemotherapy and radiotherapy, both 
of which are known to cause elevations in circulating 
GDF15 (37, 38). Despite a paucity of research relating 
to the mechanisms of nausea and vomiting in adrenal in-
sufficiency, it is well established that these symptoms are 
responsive to glucocorticoid replacement (29). In this 
study, we demonstrate that circulating GDF15 levels are 
increased in patients with PAI temporarily deprived of 
glucocorticoid replacement therapy. In 3 independent 
cohorts, we demonstrated that short-term physiological 
glucocorticoid replacement in patients with different 
forms of PAI led to a reduction in circulating GDF15. 
Importantly, the relationship between glucocorticoid re-
placement and GDF15 appears to be dose dependent. 
Interestingly, GDF15 has been reported to have a di-
urnal rhythm with a peak at ~0000h and nadir at 
~1200h (39). Might this be entrained by the normal 
circadian rhythm of cortisol secretion? The findings in 
our study indicate that GDF15 levels were significantly 
lower when cortisol levels were artificially maintained 
at ~400 nmol/L (similar to physiological “peak” levels) 
vs ~150 nmol/L (similar to physiological “nadir” levels) 
is at least compatible with this hypothesis. The time lag 
between peak cortisol and the nadir of GDF15 would 
be expected if cortisol is having an effect on GDF15 
gene expression. Further insight may be gained from 
the measurement of circulating GDF15 levels in human 
populations with disrupted circadian rhythms.
Although we did not directly address the issue in these 
studies it is interesting to speculate whether GDF15 
might play a role in the well-established effects of gluco-
corticoids on appetite and energy intake outside the set-
ting of adrenal insufficiency, including, for example, in 
states of endogenous or pharmacological glucocorticoid 
excess (40). These effects of glucocorticoids accumulate 
with time. However, a limitation of our studies is that 
we only studied acute manipulations of glucocorticoids 
and for ethical reasons we could only study patients 
with short-term withdrawal of therapy. An additional 
limitation of our studies is that we did not formally ad-
dress the contribution of mineralocorticoid deficiency to 
GDF15 levels and the CAH cohort continued to take 
prescribed mineralocorticoid replacement during the 
study. However, it is worth noting that anorexia, weight 
loss, nausea, and vomiting are characteristic features 
of untreated isolated adrenocorticotropin deficiency, a 
condition that selectively lowers glucocorticoid (41) ra-
ther than mineralocorticoid levels.
Despite pharmacological replacement of the gluco-
corticoid and mineralocorticoid deficiencies, concerns 
remain regarding quality of life, cardiometabolic and 
bone health among patients affected by PAI (42). In 
clinical practice there is considerable heterogeneity in 
glucocorticoid and mineralocorticoid replacement regi-
mens used to treat PAI (43, 44). These observations fuel 
interest in determining the optimal glucocorticoid re-
placement strategy of patients with PAI (45) as the cur-
rent empiric approaches particularly to glucocorticoid 
dosing cannot account for the many factors which in-
fluence hormone action at its target tissue. Our study 
did not extend to exploring the tissue/s from which in-
creased circulating GDF15 was produced. In principle 
GDF15 may be considered as target tissue derived cir-
culating biomarker of glucocorticoid exposure. In prac-
tice, however, the utility of GDF15 as a biomarker of 
tissue exposure to glucocorticoid is likely hampered 
by the fact GDF15 is also influenced by a wide range 
of physiological and pathological states. This was ex-
emplified in one participant in the  pharmacologically 
induced glucocorticoid deficiency  cohort (Participant 
no. 6 (46)) who did not modulate their GDF15 level in 
Figure 3. Dose effect of hydrocortisone replacement on 
circulating GDF15. Serum GDF15 was measured in n = 20 healthy 
male volunteers with metyrapone inhibited endogenous cortisol 
synthesis who received low, medium, and high dose hydrocortisone 
replacement on three separate occasions. Exposure to increasing 
doses of hydrocortisone was associated with significantly lower 
GDF15 levels. Data expressed as mean ± standard deviation and 
compared using a one-way analysis of variance and post-hoc Tukey 
test, **P < .01, ***P < .001, ****P < .0001.
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response to increasing doses of hydrocortisone unlike 
the other participants.
In conclusion, we have demonstrated that circu-
lating GDF15 levels are elevated in untreated PAI pa-
tients compared to matched healthy controls and that 
glucocorticoid replacement corrects the elevated GDF15 
levels. GDF15 responds to glucocorticoid replacement in 
a dose-dependent manner. Further investigation of the 
causal nature of the relationship between glucocorticoid 
deficiency, elevated circulating levels of GDF15 and 
symptoms of anorexia, weight loss, nausea and vomiting 
is warranted. Such studies should be facilitated in the 
near future by the availability of humanized monoclonal 
antibodies designed to block GDF15 action.
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